Beginner's Guide to Biotech PDUFA Trading
Everything you need to understand the terminology, the process, and the scores on Submarine Catalyst. Start here if you're new to biotech catalyst trading.
What is a PDUFA Date?
The deadline by which the FDA must respond to a drug application. When a pharmaceutical company submits a new drug for approval, the FDA sets a date — typically 10-12 months out — by which they will give their decision. This date is the PDUFA date.
PDUFA dates are the most important catalysts in biotech trading. They're the moments when the FDA says yes or no, and stocks can move 20-100% in either direction within hours. That's why traders plan around them and why Submarine Catalyst scores every one.
The FDA can act on or before the PDUFA date. Early approvals happen — DNLI was approved days before its scheduled date. The FDA rarely extends beyond the PDUFA date without notifying the company first.
The FDA Approval Process
Before a drug reaches its PDUFA date, it goes through years of development. Here's the simplified timeline:
Preclinical: Lab and animal testing. No humans involved yet. Most drugs fail here.
Phase 1: First human testing. 20-100 healthy volunteers. Tests safety and dosing. "Is this drug safe?"
Phase 2: Expanded testing. 100-300 patients with the disease. Tests whether the drug actually works. "Does it do anything?"
Phase 3: Large-scale trials. 1,000-5,000+ patients. The definitive test. Results from Phase 3 are what the FDA bases their decision on. "Does it work well enough to approve?"
FDA Filing (NDA/BLA): The company submits all their data to the FDA. The FDA sets the PDUFA date.
PDUFA Date: The FDA gives their decision. This is where the scanner focuses.
Application Types
An application to approve a new chemical drug (small molecule). Most common type. Think pills and tablets.
An application to approve a biological product — things made from living cells like antibodies, gene therapies, and vaccines. These are typically more complex and expensive than small molecule drugs.
An application to expand the use of an already-approved drug to a new indication (disease), a new patient population, or a new dosage form. The drug is already on the market — this just adds another approved use.
An application to approve a generic version of an already-approved drug. These are cheaper and faster because the drug has already been proven to work — the generic just needs to show it's the same.
Why this matters for trading: An NDA or BLA for a first-ever drug is a much bigger catalyst than an sNDA for a label expansion. First approvals can move a stock 30-100%. Label expansions typically move 5-15%. The scanner accounts for this in both the PoA score and the Sell-The-News Risk assessment.
Possible FDA Outcomes
The FDA says yes. The company can begin selling the drug. This is the outcome biotech longs are hoping for. However, approval does NOT always mean the stock goes up — see our education page on sell-the-news dynamics.
The FDA says no — for now. A CRL identifies issues the company must fix before the drug can be reconsidered. Issues range from minor (manufacturing quality, labeling) to severe (clinical data insufficient, safety concerns). The stock typically drops 30-70% on a CRL.
The FDA pushes the PDUFA date back, usually by 3 months. This happens when the company submits significant new information late in the review, triggering a "major amendment" that resets the review clock. Not as bad as a CRL but still negative — the stock typically drops 10-25%.
The FDA rejects the application before even reviewing it. The submission was so incomplete that the FDA won't begin the review process. This is the worst possible outcome — it means the application was fundamentally flawed. Extremely rare but devastating (usually -50% or worse).
Advisory Committees (AdCom)
Before some PDUFA decisions, the FDA convenes a panel of outside experts to review the drug and vote on whether it should be approved. The FDA isn't required to follow the vote, but they almost always do. AdCom votes are highly predictive of FDA decisions.
How to read AdCom votes:
Unanimous (10-0, 12-0, etc.): Extremely bullish. Historically ~99% of unanimous positive votes lead to approval. However, because the outcome is so expected, the stock often doesn't move much on the actual approval — the move already happened when the AdCom vote was announced. This is a classic sell-the-news setup.
Strong (8-2, 9-3): Very bullish. 90%+ approval rate. Some uncertainty remains, so the stock can still pop on approval.
Close (6-4, 5-4): Uncertain. 60-70% approval rate. Significant upside if approved because the market wasn't sure. But also real risk of a CRL.
Negative (3-7, 2-8): Bearish. FDA rarely approves against a negative vote. The stock has likely already dropped on the AdCom result.
Special FDA Designations
Given to drugs that show substantial improvement over existing treatments for serious conditions. The FDA provides more intensive guidance and expedited review. Drugs with breakthrough designation have historically higher approval rates (~90%).
Given to drugs treating rare diseases affecting fewer than 200,000 patients in the US. Benefits include tax credits, reduced fees, and 7 years of market exclusivity after approval. Orphan drugs have a high approval rate (~86%) but limited revenue potential due to the small patient population.
The FDA reviews the application in 6 months instead of the standard 10-12 months. Given to drugs that offer significant improvement over available therapies. Priority review drugs have higher approval rates (~81%).
Allows the company to submit sections of the application on a rolling basis instead of all at once. Speeds up the path to the PDUFA date. Slightly higher approval rates (~80%).
The FDA approves a drug based on a surrogate endpoint (like tumor shrinkage) rather than the ultimate clinical outcome (like survival). The drug reaches the market faster, but the company must run a confirmatory trial afterward. If the confirmatory trial fails, the FDA can withdraw the approval. This adds ongoing risk even after the PDUFA is resolved.
A transferable voucher awarded to companies that get certain drugs approved (tropical disease, rare pediatric, etc.). The voucher can be sold to any other company for $100-110M+ — it lets the buyer skip to the front of the FDA review line for any future drug. PRV eligibility adds significant value on approval beyond just the drug revenue.
Submarine Catalyst Scanner Terms
The scanner's estimate of how likely the FDA is to approve this drug, expressed as a percentage. Calculated using indication-specific base rates from published medical literature (Hay et al. 2014, Wong et al. 2019), modified by AdCom votes, review pathway, special designations, prior CRL history, and SEC filing signals.
Measures the trade asymmetry — how much the stock could move up relative to how much it could move down. A high convexity score means the potential upside significantly exceeds the potential downside. Factors include proximity to PDUFA date, how depressed the stock price is relative to its 52-week high, short interest (squeeze potential), and market cap.
A composite score (0-100) combining the PoA (60% weight) and Convexity (40% weight). This is the scanner's overall assessment of the setup quality — not just whether it gets approved, but whether it's a good trade.
A score (0-100) predicting whether an FDA approval will actually move the stock price up. A HIGH STN risk means the approval is likely already priced in and the stock may drop on good news. A LOW STN risk means there's genuine surprise value in the approval and the stock should move up. This score exists because of the RCKT lesson — approval ≠ stock move.
🚀 ELITE — Final Score ≥ 72. Highest conviction setup. Strong PoA + strong trade asymmetry.
⚡ STRONG — Final Score ≥ 58. Above-average setup worth serious consideration.
🟡 WATCH — Final Score ≥ 42. Moderate setup. May have good PoA but limited trade asymmetry, or vice versa.
⚪ WEAK — Final Score < 42. Below-average setup. High risk or low asymmetry.
The scanner's overall assessment of setup quality based on all eight risk layers combined. This is not a recommendation — it's a composite research signal that describes the data profile of the setup.
✅ STRONG SETUP — Multiple favorable signals across all risk layers. Approval not priced in, limited dilution risk, favorable TAM ratio.
✅ FAVORABLE — Above-average signal alignment. Most risk layers positive with manageable concerns.
⚠️ MIXED SETUP — Conflicting signals. Some positive indicators offset by elevated sell-the-news or dilution risk.
⚠️ CAUTIOUS — Elevated risk profile. Multiple warning signals present across risk layers.
🚨 UNFAVORABLE — Significant negative signals. Approval likely priced in, dilution threat elevated, or TAM insufficient.
Compares the estimated Total Addressable Market (annual peak revenue) of the drug's indication to the company's current market cap. This ratio tells you whether the stock has room to move on approval. A company worth $500M with a drug targeting a $10B market has a 20x TAM/Cap ratio — significant upside potential. A company worth $2B with a drug targeting a $200M market has a 0.1x ratio — the drug can't meaningfully move the stock.
🚀 10x+ — Drug market dwarfs company value. Massive potential upside on approval.
✅ 3x–10x — Significant upside. Drug market substantially exceeds company value.
⚠️ 1x–3x — Moderate. Drug market roughly equals company value.
🔴 <1x — Limited upside. Drug market is smaller than the company — stock may not move much even on good news.
A 0-100 score estimating how likely the company is to become an acquisition target. Biotech M&A is a major source of returns — small companies with first-in-class approved drugs are frequently acquired at 40-100% premiums. The scanner evaluates: first-in-class status, orphan drug designation, PRV (Priority Review Voucher) eligibility, existing partnerships, commercial infrastructure, market cap tier, and therapeutic area M&A history.
HIGH (70+) — Prime acquisition target. Multiple buyout indicators present.
MODERATE (50-69) — Potential acquisition interest. Some favorable indicators.
LOW (30-49) — Limited acquisition likelihood based on current profile.
UNLIKELY (<30) — Large or established company, unlikely single-asset acquisition play.
Real-time scanning of SEC EDGAR filings for capital raise signals near PDUFA dates. Many biotech companies raise money immediately after approval — diluting shareholders and destroying post-approval gains. The radar detects these signals before they happen.
🚨 424B5 — Prospectus supplement filed. The company is actively preparing to sell shares. Highest urgency dilution signal.
🚨 ATM Active — At-the-market offering in place. Company can sell shares daily without announcement.
⚠️ S-3 Shelf — Shelf registration active. Company can issue shares at any time without further SEC approval.
⚠️ Sales Agent Change — New investment bank added as sales agent — often precedes a capital raise.
A Complete Response Letter (CRL) is the FDA's way of saying "not approved yet — fix these issues." The scanner tracks CRL history because it directly impacts both approval probability and sell-the-news dynamics.
CRL for CMC — FDA rejected due to manufacturing/chemistry issues. These are typically fixable and resubmission success rates are high (~88%).
CRL for Clinical — FDA rejected due to efficacy or safety concerns. Much harder to fix. Resubmission carries meaningful risk.
Class 1 Resubmission — 6-month FDA review. Company submitting significant new data in response to CRL.
Class 2 Resubmission — 2-month FDA review. Limited new data — typically a label change or CMC fix.
Why CRL history matters for sell-the-news: When a drug gets a CRL and then resubmits, the market already expects approval on the second attempt. This creates HIGH STN Risk — the approval is priced in before it happens. RCKT was a resubmission after CRL, with a unanimous AdCom. The market expected approval. It got approved. The stock dropped 20%.
CMC refers to the manufacturing and quality control aspects of a drug. FDA rejections for CMC issues are generally more fixable than clinical rejections — they involve things like facility inspections, manufacturing processes, stability data, or packaging. The scanner flags active CMC concerns because they can cause unexpected CRLs even when the clinical data is strong.
Trading Terms for PDUFA Events
An event with two possible outcomes — the drug is approved or it's not. PDUFA dates are binary events. The stock will move significantly in one direction or the other. There's no middle ground, which is why position sizing and risk management are critical.
When a stock drops after positive news because the good news was already expected and priced into the stock before the announcement. The announcement removes the catalyst people were holding for, and they sell. This is the most common way retail traders lose money on biotech — buying before a PDUFA expecting a pop that never comes.
The percentage of a stock's available shares that have been sold short (borrowed and sold with the expectation of buying back lower). High short interest can mean institutions are betting against the stock — or it can mean a short squeeze is possible if the stock moves up sharply and shorts are forced to cover.
When a stock with high short interest moves up sharply, forcing short sellers to buy back shares to cut their losses. Their buying pushes the price even higher, forcing more shorts to cover, creating a feedback loop. This is how some biotech stocks move +50-100% on approval when short interest is elevated.
When a company issues new shares to raise money, reducing the value of existing shares. Many small-cap biotechs dilute within weeks of FDA approval to fund the drug's commercial launch. If you hold through approval, watch for secondary offering announcements — they typically drop the stock 10-20%.
An SEC filing that means the company is actively preparing to sell securities (shares or debt). When filed before a PDUFA date, it's the strongest signal that dilution is coming on approval. The company plans to sell shares into the approval spike. RCKT filed a 424B5 before their PDUFA and dropped 20% on approval.
An SEC filing that gives the company pre-approval to issue shares at any time without further SEC review. It's like a loaded weapon — they can sell shares whenever they want without warning. If a company has an active S-3 going into a PDUFA, expect a secondary offering within weeks of approval.
A program that lets the company sell shares gradually into the open market without announcing a formal offering. It's a slow, invisible drip of dilution. The stock drifts down over weeks as shares are quietly sold into daily volume.
Debt that converts into shares at a set price. When the stock spikes on approval, noteholders convert their debt into shares and sell — creating delayed dilution that hits weeks after the PDUFA event.
The manufacturing quality standards the FDA requires. A CRL for CMC issues means the drug works but the manufacturing process isn't good enough yet. These are generally fixable, and resubmissions after CMC-only CRLs have high approval rates. A CRL for clinical issues is much more serious.
How to Read a Scanner Card
When you look at a ticker on the Submarine Catalyst scanner, here's what to focus on:
1. Setup Quality — The big-picture signal. STRONG SETUP and FAVORABLE mean multiple risk layers are aligned positively. CAUTIOUS and UNFAVORABLE mean warning signals are present. Start here.
2. PoA Score — Is approval likely? Above 70% is strong. Below 55% means real CRL risk.
3. STN Risk — Will approval actually move the stock? HIGH means approval is likely priced in. LOW means genuine surprise value remains.
4. TAM / Cap Ratio — Can the stock actually move? A 10x+ ratio means massive upside potential. Below 1x means the drug market is smaller than the company — limited room even on good news.
5. Dilution Radar — Is a capital raise hiding in SEC filings? ATM offerings, 424B5 filings, and shelf registrations near PDUFA dates are the signals that destroy post-approval gains.
6. Buyout Probability — Could this company get acquired? First-in-class orphan drugs with no commercial infrastructure are prime targets for 40-100% acquisition premiums.
7. CRL History — Has this drug been rejected before? CRL-for-CMC is fixable. CRL-for-clinical is risky. Resubmissions have HIGH STN Risk because approval is expected.
8. Grade — ELITE and STRONG setups have the best composite scores. WATCH means proceed with caution.
9. Flags — Read every flag. They tell you the specific factors driving the scores.
10. Deep Dive — Click any ticker for the full AI-generated analysis with pipeline overview, price scenarios, and buyout assessment.
Next Steps
Read: How Institutions Trade PDUFA Events — understand sell-the-news dynamics and short selling mechanics.
Study: Post-Catalyst Behavior Patterns — learn the five ways stocks typically behave after FDA decisions.
Browse: Full Calendar — see all 870+ biotech companies with PDUFA events, earnings, and buyout signals.
Compare: Compare Tool — pick any 2-4 companies and compare every risk layer side by side.
Verify: Track Record — see every prediction we've made and how it played out, including actual stock moves.
Subscribe: Unlock full scanner scores, setup quality ratings, AI deep dives, and all risk layers for every event.
870+ companies · Setup quality · TAM/Cap · Buyout scoring · Dilution radar · AI deep dives